Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02113020
Recruitment Status : Completed
First Posted : April 14, 2014
Last Update Posted : October 21, 2014
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:
The objective of this clinical trial is to examine the clinical pharmacology properties of TAK-233 in healthy female subjects

Condition or disease Intervention/treatment Phase
Clinical Pharmacology Drug: TAK-233 Drug: Placebo Phase 1

Detailed Description:
The primary objective of this study is to examine the pharmacodynamics and the safety of TAK-233 administered as a single dose in healthy women.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects
Study Start Date : February 2014
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Arm Intervention/treatment
Experimental: TAK-233
Oral administration
Drug: TAK-233
Oral administration of TAK-233

Placebo Comparator: Placebo
Oral administration
Drug: Placebo
Oral admininstration of Placebo




Primary Outcome Measures :
  1. Change from baseline in motor threshold for urethral sphincter contraction. [ Time Frame: 0.5 hours post-dose ]
  2. Change from baseline in motor threshold for urethral sphincter contraction. [ Time Frame: 3 hours post-dose ]
  3. Change from baseline in motor threshold for urethral sphincter contraction. [ Time Frame: 6 hours post-dose ]

Secondary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: Up to 28 days ]
    Treatment emergent adverse events, vital signs, weight, safety ECG, and clinical laboratory tests (hematology, serum chemistry, and urinalysis).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects who understand the contents of this clinical trial and who the investigator or sub-investigator consider able to comply with the procedures of the clinical trial
  2. Subjects who can sign the informed consent form and can date the form without assistance before starting the procedures of the clinical trial
  3. Healthy Japanese women
  4. Subjects aged ≥ 20 and ≤ 40 years at the time of consent
  5. Subjects with body weight ≥ 45 kg and BMI ≥18.5 and ≤ 25.0 kg/m2 at the time of screening
  6. Women of child bearing potential who agree to take specified contraceptive measures regularly from the time of consent until 4 weeks after the end of the last assessment in the fourth treatment period

Exclusion Criteria:

  1. Subjects who received TAK-233 within 16 weeks before the start of initial administration
  2. Subjects who have previously received TAK-233 during treatment or during participation in another clinical trial
  3. Employees of the medical institution conducting this clinical trial and their family/dependents (e.g., husband or wife, parents, children, and siblings), or subjects who may be coerced to agree to participate in the clinical trial
  4. Subjects with poorly controlled and clinically significant neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal (including chronic costiveness), urological (including dysuria), autoimmune, endocrine, or psychiatric diseases or other abnormalities which may affect the subject's participation in the clinical trial or results of the clinical trial
  5. Subjects with hypersensitivity to TAK-233 related substances, or excipients of these products
  6. Subjects whose urine tested positive for drug abuse at screening
  7. Subjects with a history of drug abuse (defined as the use of illegal drugs) or alcohol dependence within 52 weeks before the screening assessments, or subjects who are not willing to stop alcohol intake or drug use during their participation in the clinical trial
  8. Subjects who need to take prohibited concomitant medications, vitamins, or foods listed in listed in what?
  9. Pregnant or lactating women, women expecting to be pregnant before giving consent, during this clinical trial, or within 4 weeks after the completion of this clinical trial, or women who are planning to donate their ova during this period
  10. Subjects with currently active cardiovascular diseases, central nervous system diseases, hepatic diseases, hematopoietic diseases, renal failure, metabolic disorders, endocrine disorders, serious allergies, asthma, hypoxemia, hypertension, convulsion, allergic exanthema, or urological disorders (subjects with peptic ulcer, convulsive disorders, or arrhythmia also fall this category)
  11. Subjects that have any of the following diseases/surgical interventions that may affect drug absorption: digestive system disorders (malabsorption, esophageal reflux, peptic ulcer, erosive oesophagitis, frequent heartburn (at least once a week), or surgical interventions (e.g., cholecystectomy), or subjects who have had prior history of any of these diseases/surgical interventions within the last 24 weeks
  12. Subjects with a history of cancer (excluding subjects whose basal cell carcinoma has been in remission for at least 5 years
  13. Subjects that have tested positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, or syphilis serological reaction at screening
  14. Subjects who took nicotine-containing products (e.g., cigarette, pipe tobacco, cigar, chewing tobacco, nicotine patch, and nicotine gum) within 28 days before hospitalization
  15. Subjects for whom blood collection from peripheral veins is difficult
  16. Subjects who donated at least 200 mL of whole blood within 4 weeks before the start of the initial administration, or subjects who donated at least 400 mL of whole blood within 16 weeks before the start of the initial administration
  17. Subjects who donated at least 400 mL (in total) of whole blood within 52 weeks before the start of the initial administration
  18. Subjects who donated blood components within 2 weeks before the start of the initial administration
  19. Subjects with clinically significant abnormalities on the electrocardiogram recorded at screening or hospitalization (Day -1 of the first treatment period)
  20. Subjects who had a QTcF interval of > 470 msec or a PR interval of < 120 msec or > 220 msec on the electrocardiogram recorded at screening or hospitalization
  21. Subjects with a systolic blood pressure of < 100 mmHg or > 140 mmHg and a diastolic blood pressure of < 60 mmHg or > 90 mmHg at screening or hospitalization
  22. Subjects with a heart rate of < 50 bpm or > 90 bpm at screening or hospitalization

22. Subjects unlikely to comply with the protocol, or subjects the investigator or sub-investigator considers ineligible for participation in the clinical trial due to other reasons


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02113020


Locations
Layout table for location information
Japan
Kumamoto-shi, Kumamoto, Japan
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: General Manager Takeda
Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02113020    
Other Study ID Numbers: TAK-233/CPH-003
U1111-1152-9381 ( Registry Identifier: WHO )
First Posted: April 14, 2014    Key Record Dates
Last Update Posted: October 21, 2014
Last Verified: October 2014